Sleep Optimization: Evidence-Based Fundamentals (and What the Marketing Gets Wrong)

Sleep research divides cleanly into two categories: well-replicated findings with strong evidence, and a large commercial ecosystem of products, apps, and supplements with weak or no controlled trial support. This article focuses on the former. The basics — consistent sleep timing, adequate duration, and structured behavioural intervention when sleep is genuinely impaired — carry far more evidential weight than any tracking device, cooling pad, or supplement stack. That is not dismissiveness toward technology; it is an honest read of where the controlled trials point.

Cognitive Behavioural Therapy for Insomnia (CBT-I) is a structured multicomponent programme that combines sleep restriction, stimulus control, sleep hygiene education, and cognitive restructuring. It is the only sleep intervention with a strong clinical guideline recommendation from the American Academy of Sleep Medicine — placing it above all pharmacological alternatives as the first-line treatment for chronic insomnia disorder.

CBT-I typically involves four to eight sessions with a trained provider, though digital and self-guided versions have also shown benefit in trials. The treatment gains appear durable: follow-up data suggest continued improvement without ongoing intervention.

Large meta-analyses consistently show a U-shaped relationship between nightly sleep duration and cardiovascular and metabolic health outcomes. Both insufficient and excessive sleep are associated with elevated risk — with the lowest risk concentrated in the 7–8 hours range for most adults. The National Sleep Foundation and CDC both recommend 7–9 hours for adults aged 18–64.

Importantly, the vast majority of this evidence is observational: tracking what people already do rather than randomising them to sleep durations. This means confounding is a real concern — sicker people may sleep more, and high-stress individuals may sleep less. The association is consistent and large enough across studies to be taken seriously, but 'associated with elevated risk' is not the same as 'causes elevated risk.'

Beyond duration, the regularity of sleep timing appears independently relevant to health. 'Social jetlag' — the mismatch between biological sleep timing and socially imposed schedules (typically measured as the difference in sleep midpoint between weekdays and weekends) — is associated with metabolic and cardiovascular markers in population studies.

This is important context for understanding why simply sleeping enough hours is not the whole story. Irregular sleep timing, even at sufficient total hours, disrupts circadian entrainment — the biological alignment of the body's clocks with the external light-dark cycle. Consistent wake and sleep times are a central component of CBT-I's stimulus control technique, and they are among the most universally supported sleep hygiene recommendations.

The underlying mechanism is well-established: light in the blue-wavelength range (460–480 nm) activates retinal cells that signal the brain's master clock to inhibit melatonin secretion. When this happens in the hours before bed, it suppresses the natural melatonin rise that facilitates sleep onset and can delay circadian phase. This is physiology, not speculation.

What is less certain is whether commercially available blue-blocking glasses produce meaningful sleep improvements in healthy people who do not have sleep disorders. A 2020 systematic review and meta-analysis found small-to-medium objective effects from wearing blue-blocking glasses, with wide confidence intervals that crossed zero for some outcomes. Crucially, benefits were substantially larger for individuals who already had sleep disorders than for healthy sleepers. Marketing claims that normalise blue-blocking glasses as an essential daily tool for everyone outrun the current evidence.

Melatonin is widely sold as a sleep aid and widely assumed to work for general insomnia. The evidence is more nuanced. For chronic insomnia disorder, a 2022 review of systematic reviews found mixed results when melatonin was compared to placebo, with some guidelines — including the VA/DoD clinical practice guideline — recommending against its use for this condition.

Where melatonin has better-supported utility is in circadian phase-shifting: helping the body clock adapt to jet lag or shift work by timing supplementation relative to the new schedule. This is a mechanistically different use case from treating primary insomnia, and the two are often conflated in consumer contexts.

For short-term use, the safety profile is generally considered favourable. What is lacking is convincing controlled evidence that melatonin meaningfully treats chronic insomnia in otherwise healthy adults, compared to either placebo or CBT-I.

Core body temperature naturally declines during the transition to sleep. A cooler sleep environment is thought to support this drop, and most sleep medicine guidance recommends keeping the bedroom between approximately 18–20 °C (65–68 °F) for general adults. A 2023 observational study of older adults (n = 50, ~11,000 person-nights, published in Science of the Total Environment) found that sleep efficiency declined 5–10% as ambient temperature rose above 25 °C (77 °F) — and that considerable individual variation exists.

The temperature-sleep relationship has a plausible mechanism and consistent expert consensus behind it, but controlled trial evidence in general populations (rather than older adults or specific clinical groups) is limited. Darkness and minimising noise during sleep are similarly recommended with strong mechanistic rationale but relatively sparse large-scale RCT evidence compared to CBT-I. They belong in a foundational sleep hygiene protocol, with the honest note that the evidence base is not as deep as that for CBT-I or sleep duration.